- First
ever data demonstrating anti-leukemic effect of Actimab-A in FLT3
Mutant AML models
NEW
YORK, Aug. 31, 2023 /PRNewswire/
-- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM)
(Actinium or the Company), a leader in the development of targeted
radiotherapies, today details three abstracts accepted for poster
presentation at the upcoming Society of Hematologic Oncology (SOHO)
2023 Annual Meeting, which will be held in Houston, September
6-9, 2023.
Details of the SOHO poster presentations:
Poster Title: The Randomized Phase III SIERRA (Study
of Iomab-B in Elderly Relapsed or Refractory AML) Trial: Successful
Allogeneic Hematopoietic Stem Cell Transplantation Using Treatment
With Iomab-B-Led Regimen for Patients With Active, Relapsed or
Refractory AML With Failed Targeted Therapies
Poster: AML-521
Session: September 6,
6pm CT, Grand Ballroom (Level 3)
Poster Title: Sequential Salvage Chemotherapy and
Lintuzumab-Ac225 in Relapsed/Refractory AML Results in Deep
Responses and Prolonged Survival in Adverse Risk Acute Myeloid
Leukemia (AML) and in AML Patients that Received Prior Venetoclax
Therapy
Poster: AML-530
Session: September 6,
6pm CT, Grand Ballroom (Level 3)
Poster Title: Antileukemic Activity of
Lintuzumab-Ac225 in Preclinical Model of FLT3 Mutant AML
Poster: AML-502
Session: September 6,
6pm CT, Grand Ballroom (Level 3)
About Actinium
Actinium develops targeted radiotherapies to meaningfully
improve survival for people who have failed existing oncology
therapies. Advanced pipeline candidates Iomab-B (pre-BLA), an
induction and conditioning agent prior to bone marrow transplant,
and Actimab-A (National Cancer Institute CRADA pivotal development
path), a therapeutic, have demonstrated potential to extend
survival outcomes for people with relapsed and refractory acute
myeloid leukemia. Actinium plans to advance Iomab-B for other
blood cancers and next generation conditioning candidate Iomab-ACT
to improve cell and gene therapy outcomes. Actinium's
technology platform is the basis for collaborations with Astellas
Pharma for solid tumors, AVEO Oncology/LG Chem Life Sciences for
HER3 solid tumors, and EpicentRx for its CD47 targeting agent, and
several internal programs in solid tumors. Actinium holds
more than 200 patents and patent applications.
For more information, please visit:
https://www.actiniumpharma.com/
Forward-Looking Statements
This press release may contain projections or other
"forward-looking statements" within the meaning of the
"safe-harbor" provisions of the private securities litigation
reform act of 1995 regarding future events or the future financial
performance of the Company which the Company undertakes no
obligation to update. These statements are based on management's
current expectations and are subject to risks and uncertainties
that may cause actual results to differ materially from the
anticipated or estimated future results, including the risks and
uncertainties associated with preliminary study results varying
from final results, estimates of potential markets for drugs under
development, clinical trials, actions by the FDA and other
governmental agencies, regulatory clearances, responses to
regulatory matters, the market demand for and acceptance of
Actinium's products and services, performance of clinical research
organizations and other risks detailed from time to time in
Actinium's filings with the Securities and Exchange Commission (the
"SEC"), including without limitation its most recent annual report
on form 10-K, subsequent quarterly reports on Forms 10-Q and Forms
8-K, each as amended and supplemented from time to time.
Contact:
Matthew Beck
Vice President Investor Relations & Communications
mbeck@actiniumpharma.com
(917) 415-1750
View original content to download
multimedia:https://www.prnewswire.com/news-releases/actinium-pharma-highlights-three-abstracts-accepted-for-poster-presentation-at-the-soho-2023-annual-meeting-301914404.html
SOURCE Actinium Pharmaceuticals, Inc.